Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Division of Hepato-Biliary-Pancreatic Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Ann Surg Oncol. 2022 Dec;29(13):8385-8393. doi: 10.1245/s10434-022-12301-w. Epub 2022 Aug 16.
Colorectal cancer with liver metastasis (CLM) has high postoperative recurrence rates; therefore, optimizing perioperative treatment is imperative. Postoperative carcinoembryonic antigen (CEA) can aid in detecting minimal residual disease in colon cancer following curative resection. This study aimed to identify the potential role of serum CEA following liver resection in patients with CLM.
This retrospective study was conducted at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from 2004 to 2018 and enrolled patients with CLM who underwent complete resection of primary tumors and CLM. Associations between perioperative CEA levels and characteristics of recurrence were investigated.
Recurrence was detected during a median follow-up period of 90.1 months in 343 (54.2%) out of 633 analyzed patients. Patients in the postoperative CEA level > 5 ng/ml group had a significantly higher recurrence rate (75.7% versus 50.0%, p < 0.01) and shorter time until recurrence (4.4 versus 36.9 months, p < 0.01) than those in the postoperative CEA level ≤ 5 ng/ml group. Multivariate analysis revealed that postoperative CEA level > 5 ng/ml was an independent predictor, with hazard ratios of 2.77 (p < 0.01) for recurrence-free survival (RFS) and 3.18 (p < 0.01) for overall survival (OS). Additionally, RFS was significantly shorter among patients in the postoperative CEA level > 5 ng/ml group who did not have normalized CEA levels following adjuvant chemotherapy than among those in the normalized CEA group.
The postoperative and post-adjuvant chemotherapy CEA levels in the CEA level > 5 ng/ml group may be predictors of RFS and OS.
结直肠癌伴肝转移(CLM)术后复发率高;因此,优化围手术期治疗至关重要。术后癌胚抗原(CEA)可辅助检测结肠癌根治性切除术后的微小残留病变。本研究旨在探讨 CLM 患者肝切除术后血清 CEA 水平的潜在作用。
本研究为回顾性研究,于 2004 年至 2018 年在日本癌症研究所医院进行,纳入行原发性肿瘤和 CLM 完全切除术的 CLM 患者。分析了围手术期 CEA 水平与复发特征的关系。
在中位随访 90.1 个月时,343 例(54.2%)患者中检测到复发。术后 CEA 水平>5ng/ml 组的复发率(75.7%比 50.0%,p<0.01)和复发时间(4.4 个月比 36.9 个月,p<0.01)均显著高于术后 CEA 水平≤5ng/ml 组。多变量分析显示,术后 CEA 水平>5ng/ml 是无病生存(RFS)和总生存(OS)的独立预测因子,风险比分别为 2.77(p<0.01)和 3.18(p<0.01)。此外,在术后 CEA 水平>5ng/ml 组中,辅助化疗后 CEA 水平未恢复正常的患者 RFS 明显短于 CEA 水平恢复正常的患者。
CEA 水平>5ng/ml 组的术后和辅助化疗后 CEA 水平可能是 RFS 和 OS 的预测因子。